0001573202-17-000006.txt : 20170706
0001573202-17-000006.hdr.sgml : 20170706
20170706111324
ACCESSION NUMBER: 0001573202-17-000006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170630
FILED AS OF DATE: 20170706
DATE AS OF CHANGE: 20170706
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RespireRx Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0000849636
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330303583
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 126 VALLEY ROAD
STREET 2: SUITE C
CITY: GLEN ROCK
STATE: NJ
ZIP: 07452
BUSINESS PHONE: (201) 444-4947
MAIL ADDRESS:
STREET 1: 126 VALLEY ROAD
STREET 2: SUITE C
CITY: GLEN ROCK
STATE: NJ
ZIP: 07452
FORMER COMPANY:
FORMER CONFORMED NAME: CORTEX PHARMACEUTICALS INC/DE/
DATE OF NAME CHANGE: 19920703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Purcell Richard David Jr.
CENTRAL INDEX KEY: 0001639306
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16467
FILM NUMBER: 17951251
MAIL ADDRESS:
STREET 1: 65 FAIR HAVEN ROAD
CITY: FAIR HAVEN
STATE: NJ
ZIP: 07704
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2017-06-30
0
0000849636
RespireRx Pharmaceuticals Inc.
RSPI
0001639306
Purcell Richard David Jr.
C/O RESPIRERX PHARMACEUTICALS INC.
126 VALLEY ROAD, SUITE C
GLEN ROCK
NJ
07452
0
1
0
0
SVP - Research and Development
Common Stock Options (to purchase shares of Common Stock)
2
2017-06-30
4
A
0
40000
0
A
2022-06-30
common stock
40000
40000
D
Common Stock Options (to purchase shares of Common Stock)
3.9
2022-01-17
common stock
40000
40000
D
Common Stock Options (to purchase shares of Common Stock)
7.3775
2021-03-31
common stock
61539
61539
D
Common Stock Options (to purchase shares of Common Stock)
6.396
2022-08-18
common stock
9231
9231
D
Common Stock Options (to purchase shares of Common Stock)
8.125
2022-06-30
common stock
6154
6154
D
These Common Stock Options vested upon issuance.
These Common Stock Options vested in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017, and are all currently vested.
The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.
These Common Stock Options vested in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016, and are all currently vested.
These Common Stock Options vested in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016, and are all currently vested.
The Common Stock Options vested in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015, and are all currently vested.
/s/ Richard D. Purcell, Jr.
2017-07-05